Noreen Henig - 24 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Reporting relationship: Chief Medical Officer
Issuer ticker: KZR
Reported as of: 24 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jul 2023, 17:02:56 UTC
Prior SEC filing: 20 Jun 2023
Next SEC filing: 14 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Marc Belsky, Attorney-in-Fact

Key filing fact

Noreen Henig filed Form 4 for Kezar Life Sciences, Inc. (KZR) on 26 Jul 2023.

Key facts

This page summarizes Noreen Henig's Form 4 filing for Kezar Life Sciences, Inc. (KZR).
8 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 26 Jul 2023, 17:02.

Change

Previous filing in this sequence was filed on 20 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -300,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $4.56
Footnotes: F1, F2

KZR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +300,000
Change %
Price
Shares after: 300,000
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $2.28
Footnotes: F1, F2

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -280,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $5.45
Footnotes: F2, F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +280,000
Change %
Price
Shares after: 280,000
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 280,000
Exercise price: $2.28
Footnotes: F2, F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -180,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 180,000
Exercise price: $14.55
Footnotes: F2, F4

KZR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +180,000
Change %
Price
Shares after: 180,000
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 180,000
Exercise price: $2.28
Footnotes: F2, F4

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -220,000
Change %: -100%
Price
Shares after: 0
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220,000
Exercise price: $6.84
Footnotes: F2, F5

KZR transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +220,000
Change %
Price
Shares after: 220,000
Date: 24 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 220,000
Exercise price: $2.28
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Twenty-five percent (25%) of the shares subject to the option vested on May 1, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such vesting date.

Footnote F2

On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.

Footnote F3

One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.

Footnote F4

One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.

Footnote F5

One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.